Position in ZYME
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,558,985
+$3,558,985 QoQ
Shares Held
142,132
Ownership
0.195%
of shares outstanding
% of Portfolio
1.58%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ZYME
reported options exposure · as of Dec 31, 2025CallValue
$6,334,998
CallShares
240,600
PutValue
$563,462
PutShares
21,400
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026DIADEMA PARTNERS LP holds $177,237,458 across 73 Biotechnology names. ZYME ranks #16 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VKTX |
Viking Therapeutics, Inc.
|
525,181 | $17,089,389 | |
| 2 | COGT |
Cogent Biosciences, Inc.
|
322,764 | $12,423,186 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
54,755 | $10,351,432 | |
| 4 | TERN |
Terns Pharmaceuticals, Inc.
|
181,752 | $9,581,965 | |
| 5 | ABVX |
Abivax S.A.
|
75,944 | $8,456,364 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
148,229 | $8,373,456 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
80,872 | $7,864,802 | |
| 8 | KOD |
Kodiak Sciences Inc.
|
192,962 | $7,355,711 |
All Filings in ZYME
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,558,985 | 142,132 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $563,462 | 21,400 | Put | Sole | 2026-02-17 | |
| 2025-12-31 | $6,334,998 | 240,600 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $3,356,220 | 196,500 | Call | Sole | 2025-11-14 | |
| 2025-06-30 | $2,250,215 | 179,300 | Call | Sole | 2025-08-14 | |
| 2025-03-31 | $2,135,463 | 179,300 | Call | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||